Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer

Detection threshold and reproducibility of68Ga-PSMA11 PET/CT in a mouse model of prostate cancer

(2018) Katharina Lückerath et al.   JOURNAL OF NUCLEAR MEDICINE

Dosimetry of Lu-177 PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pre-therapeutic imaging and “whole body” tumor dosimetry with treatment outcomes

(2018) John A Violet et al.   JOURNAL OF NUCLEAR MEDICINE

Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy

(2017) Matthias Eiber et al.   JOURNAL OF NUCLEAR MEDICINE

Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells

(2017) Maryam Ghashghaei et al.   PROSTATE

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

(2017) Likun Li et al.   Science Signaling

Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling

(2017) Styliani Karanika et al.   Cell Reports

Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer

(2017) Likun Li et al.   Science Signaling

44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617

(2017) Christoph A. Umbricht et al.   EJNMMI Research

68 Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience

(2016) Thomas A. Hope et al.   JOURNAL OF NUCLEAR MEDICINE

Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer

(2015) Andreas Delker et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Repeated fine-needle aspiration of solid tumours in mice allows the identification of multiple infiltrating immune cell types

(2015) Christina S.E. Carroll et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

(2015) M. Bene ova et al.   JOURNAL OF NUCLEAR MEDICINE

68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies

(2015) M. Weineisen et al.   JOURNAL OF NUCLEAR MEDICINE

Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer

(2015) Vincent A. DiPippo et al.   PROSTATE

Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair

(2015) Firas L. Tarish et al.   Science Translational Medicine

Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy

(2015) B. Meller et al.   EJNMMI Research

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer

(2014) Jose D. Murga et al.   PROSTATE

Evaluation of the Genisys4, a Bench-Top Preclinical PET Scanner

(2013) K. Herrmann et al.   JOURNAL OF NUCLEAR MEDICINE

Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers

(2013) W. R. Polkinghorn et al.   Cancer Discovery

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

(2012) Howard I. Scher et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen

(2011) M. J. Evans et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Minimally invasive assessment of tumor angiogenesis by fine needle aspiration and flow cytometry

(2010) Joseph L. Sottnik et al.   ANGIOGENESIS